Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (2883)	3/20/1998 10:33:00 PM
From: Bradpalm1	Respond to of 7041

<<This shows your total lack of real understanding. The trials have long been finished.>> Oh? Which trials are you talking about? Completed trials ZON 300 and ZON 301 or ongoing trials ZON 302 and ZON 303? If these last 2 open label, 12 month "safety trials" involving 2600 men were started just last September, the EARLIEST that Vasomax' NDA could be submitted is this coming October. Right, Claud? Or does SPG and Zonagen plan on submitting Vasomax' NDA in THIS country without these FDA requested studies? Bradpalm1

To: Claud B who wrote (2883)	3/21/1998 1:33:00 PM
From: Hank	Read Replies (1) \| Respond to of 7041

If their clinical trials have long been finished, then why haven't they submitted their NDA? They should be right on PFE's heals and hyping the product all the way just like PFE has been doing with Viagra. If in fact they have collected all the clinical data on Vasomax that they ever intend to, then it just convinces me even more that SGP no longer believes that Vasomax will get FDA approval. This is not the way to compete in a highly competitive market place like pharmaceuticals.